Medical
A “living drug” that could change the way we treat cancer
Carl June is the immunotherapy pioneer behind CAR T-cell therapy: a groundbreaking cancer treatment that supercharges part of a patient’s own immune system to attack and kill tumours.
He is the Director of the Centre for Cellular Immunotherapies and Director of the Parker Institute for Cancer Immunotherapy at University of Pennsylvania’s Perelman School of Medicine .
In a talk about a breakthrough, he shares how three decades of research culminated in a therapy that’s eradicated cases of leukemia once thought to be incurable, and explains how it could be used to fight other types of cancer.
The American Society for Clinical Investigation has recognised Carl H. June, MD, as the recipient of its sixth annual Harrington Prize in Innovation. The prize recognises a physician-scientist who has advanced scientific innovation, creativity and possible clinical applications.
You may also like The Gut-Brain connection
News & Trends - Pharmaceuticals
Heart Week: Uniting patient and cardiologist voices in shaping a new future for patient outcomes
Coinciding with the start of the Heart Week (9 – 12 May), Professor Gemma Figtree, Interventional Cardiologist and Immediate Past […]
MoreNews & Trends - MedTech & Diagnostics
‘It’s a marathon not a sprint’: Industry leaders chart next steps in medtech’s sustainability journey
Ahead of World Environment Day in June, Jane Crowe, Managing Director of Cardinal Health Australia and New Zealand and Pravin […]
MoreNews & Trends - Pharmaceuticals
Vaccination accounts for almost half of mortality decline in infants
Pharma News: Researchers have mapped the impact of vaccines to mark the 50-year anniversary of the Expanded Programme on Immunisation […]
MoreNews & Trends - Pharmaceuticals
AbbVie, Pfizer and Bayer therapies to be considered at upcoming PBAC intracycle meeting
Pharma News: Therapies from AbbVie, Pfizer and Bayer are due to be considered at the Pharmaceutical Benefits Advisory Committee (PBAC) […]
More